The University of Southampton
University of Southampton Institutional Repository

Evaluation of Pro-re-Nata (PRN) and treat and extend Bevacizumab treatment protocols in Sorsby Fundus Dystrophy

Evaluation of Pro-re-Nata (PRN) and treat and extend Bevacizumab treatment protocols in Sorsby Fundus Dystrophy
Evaluation of Pro-re-Nata (PRN) and treat and extend Bevacizumab treatment protocols in Sorsby Fundus Dystrophy
Purpose:

To describe long-term outcomes with intravitreal Bevacizumab for choroidal neovascularization secondary to Sorsby fundus dystrophy.

Materials/methods:

Observational case series.

Results:

Two sisters of the same family formally diagnosed with Sorsby fundus dystrophy were followed-up for 12 years. The elder sister (S1) presented with significant decline in vision due to choroidal neovascularization in her right eye (OD). She developed choroidal neovascularization 3 years later in her left eye (OS). She was treated with Bevacizumab intravitreal injections on a on a pro-re-nata (PRN) until April 2015, when a treat-and-extend (T&E) approach was adopted. Best corrected visual acuities at the time of switch to T&E were 1.09 OD and 0.85 LogMar OS. Best corrected visual acuities at the last follow-up were LogMar 1.1 OD and 0.82 OS. Her younger sister (S2) presented with best corrected visual acuities of LogMar 0.1 OD and 0.0 OS. She developed choroidal neovascularization 5 years later in both eyes. OS developed choroidal neovascularization 18 months after her right eye. She received Bevacizumab on a pro re nata basis until April 2015 when a switch to a T&E was performed. Best corrected visual acuity in the left eye at the switch to T&E was 0.34 LogMar. At the last follow-up, best corrected visual acuities were LogMar 1.2 OD and 0.29 OS.

Conclusion:

Bevacizumab is an effective therapy for choroidal neovascularization secondary to Sorsby fundus dystrophy. A T&E protocol appears more effective compared to pro re nata protocol in minimizing recurrence of choroidal neovascularization with potential secondary scar formation or atrophy.

Best corrected visual acuity, choroidal neovascular membrane, OCT-angiography, Sorsby fundus dystrophy, tissue
1120-6721
Tsokolas, Georgios
13a8eec3-1eb7-4e76-8f04-e8e0a6d78f55
Almuhtaseb, Hussein
27fcdbb3-4784-483d-823c-c6dae6151578
Lotery, Andrew
5ecc2d2d-d0b4-468f-ad2c-df7156f8e514
Tsokolas, Georgios
13a8eec3-1eb7-4e76-8f04-e8e0a6d78f55
Almuhtaseb, Hussein
27fcdbb3-4784-483d-823c-c6dae6151578
Lotery, Andrew
5ecc2d2d-d0b4-468f-ad2c-df7156f8e514

Tsokolas, Georgios, Almuhtaseb, Hussein and Lotery, Andrew (2018) Evaluation of Pro-re-Nata (PRN) and treat and extend Bevacizumab treatment protocols in Sorsby Fundus Dystrophy. European Journal of Ophthalmology. (doi:10.1177/1120672118811568).

Record type: Article

Abstract

Purpose:

To describe long-term outcomes with intravitreal Bevacizumab for choroidal neovascularization secondary to Sorsby fundus dystrophy.

Materials/methods:

Observational case series.

Results:

Two sisters of the same family formally diagnosed with Sorsby fundus dystrophy were followed-up for 12 years. The elder sister (S1) presented with significant decline in vision due to choroidal neovascularization in her right eye (OD). She developed choroidal neovascularization 3 years later in her left eye (OS). She was treated with Bevacizumab intravitreal injections on a on a pro-re-nata (PRN) until April 2015, when a treat-and-extend (T&E) approach was adopted. Best corrected visual acuities at the time of switch to T&E were 1.09 OD and 0.85 LogMar OS. Best corrected visual acuities at the last follow-up were LogMar 1.1 OD and 0.82 OS. Her younger sister (S2) presented with best corrected visual acuities of LogMar 0.1 OD and 0.0 OS. She developed choroidal neovascularization 5 years later in both eyes. OS developed choroidal neovascularization 18 months after her right eye. She received Bevacizumab on a pro re nata basis until April 2015 when a switch to a T&E was performed. Best corrected visual acuity in the left eye at the switch to T&E was 0.34 LogMar. At the last follow-up, best corrected visual acuities were LogMar 1.2 OD and 0.29 OS.

Conclusion:

Bevacizumab is an effective therapy for choroidal neovascularization secondary to Sorsby fundus dystrophy. A T&E protocol appears more effective compared to pro re nata protocol in minimizing recurrence of choroidal neovascularization with potential secondary scar formation or atrophy.

Text
Sorsby Paper Accepted Manuscript-Date of Acceptance 17-10-2018 - Accepted Manuscript
Download (2MB)
Text
Sorsby_Paper_Accepted_Manuscript_Date_of_Acceptance_17_10_2018 - Accepted Manuscript
Restricted to Repository staff only
Request a copy
Text
Evaluation of Pro-re-Nata(PRN) and teat and Extend Bevacizumab treatment protocols in Sorsby Fundus Distrophy - Version of Record
Restricted to Repository staff only
Request a copy
Text
EJO811568 - Proof
Restricted to Repository staff only
Request a copy

More information

Accepted/In Press date: 17 October 2018
e-pub ahead of print date: 13 November 2018
Keywords: Best corrected visual acuity, choroidal neovascular membrane, OCT-angiography, Sorsby fundus dystrophy, tissue

Identifiers

Local EPrints ID: 426162
URI: http://eprints.soton.ac.uk/id/eprint/426162
ISSN: 1120-6721
PURE UUID: 712a78d5-eb1d-4e7d-9bea-348fb4238cc6
ORCID for Andrew Lotery: ORCID iD orcid.org/0000-0001-5541-4305

Catalogue record

Date deposited: 15 Nov 2018 17:30
Last modified: 16 Mar 2024 03:32

Export record

Altmetrics

Contributors

Author: Georgios Tsokolas
Author: Hussein Almuhtaseb
Author: Andrew Lotery ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×